Coronavirus vaccines shown to be effective in real-world use

1 March 2021
biontech_vaccine_large

In the UK, real-world data analyzed by Public Health England (PHE) show a high level of effectiveness for a single dose of Comirnaty, BioNTech (Nasdaq: BNTX) and Pfizer’s (NYSE: PFE) coronavirus vaccine.

The results, which provide an early look at how the vaccine is performing outside of a clinical trial setting, will reassure those who support a longer gap between the first and second dose.

Unlike other countries, the UK has broken with the tested administration schedule of the vaccine, recommending a longer 12-week gap between doses.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology